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Abstract
Significance: Nitric oxide (NO) classical and less classical signaling mechanisms (through interaction with sol-
uble guanylate cyclase and cytochrome c oxidase, respectively) operate through direct binding of NO to protein
metal centers, and rely on diffusibility of the NO molecule. S-Nitrosylation, a covalent post-translational
modification of protein cysteines, has emerged as a paradigm of nonclassical NO signaling. Recent Advances:
Several nonenzymatic mechanisms for S-nitrosylation formation and destruction have been described. Enzy-
matic mechanisms for transnitrosylation and denitrosylation have been also studied as regulators of the mod-
ification of specific subsets of proteins. The advancement of modification-specific proteomic methodologies has
allowed progress in the study of diverse S-nitrosoproteomes, raising clues and questions about the parameters
for determining the protein specificity of the modification. Critical Issues: We propose that S-nitrosylation is
mainly a short-range mechanism of NO signaling, exerted in a relatively limited range of action around the NO
sources, and tightly related to the very controlled regulation of subcellular localization of nitric oxide synthases.
We review the nonenzymatic and enzymatic mechanisms that support this concept, as well as physiological
examples of mammalian systems that illustrate well the precise compartmentalization of S-nitrosylation. Future
Directions: Individual and proteomic studies of protein S-nitrosylation-based signaling should take into account
the subcellular localization in order to gain further insight into the functional role of this modification in
(patho)physiological settings. Antioxid. Redox Signal. 19, 1220–1235.
Introduction
Nitric oxide (NO) is clearly recognized as a signalingmolecule in different pathways. A hallmark in this rec-
ognition came from the identification of NO as the endothe-
lial-derived relaxing factor (EDRF), a factor produced by
endothelial cells that induced vascular relaxation by operat-
ing on smooth muscle cells (52, 68). It was the first mammalian
gas molecule discovered as a second messenger in a signaling
pathway that included its production from L-arginine by a
family of nitric oxide synthases (NOSs), and generation of
cyclic GMP (cGMP) after the activation of soluble guanylate
cyclase (sGC) by NO binding through a high-affinity metal
coordination bond (26, 127). This may be considered as the
‘‘classical’’ mechanism of NO signaling (103, 106), and it in-
cludes a clear example of paracrine signaling, as NO pro-
duced in endothelial cells reacts with sGC located in smooth
muscle cells, taking advantage of its ability to diffuse across
biological membranes. In a similar way, NO produced in one
neuron diffuses and acts upon surrounding neurons. Another
well-established but ‘‘less classical’’ signaling mechanism of
NO operates through the inhibition of cytochrome c oxidase,
the complex IV of the oxidative phosphorylation system. Both
signaling mechanisms rely on direct binding of NO to protein
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metal centers through coordination chemistry (reviewed in
Refs. 103–106).
In addition, several ‘‘nonclassical’’ nitric oxide signaling
mechanisms have been described, which rely mainly on co-
valent post-translational protein modification by a series of
reactive nitrogen species (RNS) derived from the reaction of
NO with other small molecules, including free radicals. Tyr-
osine nitration is associated with formation of peroxynitrite
(ONOO - ) and nitrogen dioxide (NO2), and is considered
mainly as an irreversible modification that can impact on
some signaling pathways (69, 124, 133, 145). Cysteine residues
can be oxidized following RNS formation: ONOO - induces
formation of oxygenated forms (sulfenic acid, - SOH; sulfinic
acid, - SO2H; sulfonic acid, - SO3H), and S-glutathionylation
and other forms of S-thiolation are induced both by ONOO -
and nitrosothiol formation (3, 103, 105, 106, 111, 134, 157, 163).
S-Nitrosylation (also called S-nitrosation; see Refs. 42, 73,
104 for a discussion of the terminology) has emerged as one of
the main mechanisms of nonclassical NO signaling. It implies
the formation of a nitrosothiol (or thionitrite, R-S-N = O) at a
cysteine residue, a subtle modification that has been shown to
alter the functionality of a number of proteins. There are
several reviews that highlight the particular characteristics of
S-nitrosylation supporting its relevance as a mechanism of
redox signaling related to NO production, as well as its im-
plications in (patho)physiology in several species (35, 44, 61,
73, 83, 90, 104, 105, 141, 160). At least for some proteins, it has
been shown that S-nitrosylation leads to disulfide formation
(including S-glutathionylation), so it could be considered as
an intermediate to such more stable modifications (reviewed
in Refs. 73, 103, 105). For each case, detailed studies could
establish if the different PTMs may have the same or differ-
ent functional consequences, but it seems clear that this pos-
sibility has be integrated when studying signaling by
S-nitrosylation.
Our aim is to review the factors that confer specificity to S-
nitrosylation in order to be considered a signaling mecha-
nism, with the proposal that its signaling function is exerted
mainly in the short range, close to the NO producing sources
(mainly NOS enzymes), and thus very dependent on their
precise subcellular localization (Fig. 1). In addition, we pro-
vide some examples in which this short-range signaling oc-
curs in the context of specific human and mammalian cell
systems.
Biochemistry of S-Nitrosylation Specificity
Nonenzymatic biochemistry of S-nitrosylation formation
Several biochemical mechanisms have been postulated for
nitrosothiol formation without requiring the presence of en-
zymes to catalyze it. Direct reaction of NO with cysteine res-
idues is only relevant when the thiyl radical (P-S) has been
formed,
P-S þ NO/P-S-NO
which is relatively rare. This poses a substantial difference
with classical and less classical NO signaling mechanisms,
which are based on the direct reaction of NO with target
proteins, and in which specificity relies on structural deter-
minants that favor NO binding to particular metal centers.
In the case of S-nitrosylation, the formation of other RNS is
required, as the result of the reaction of NO with other
species.
Reactions of NO with O2 form a series of nitrogen oxides,
with different oxidation states for the N atoms; among them,
N2O3 is considered as a main nitrosating agent producing
nitrite and a nitrosothiol:
N2O3þRSH/RSNOþHþ þNO2
However, the implication of N2O3 as a relevant nitrosating
agent in biochemical environments has been challenged,
mainly because its formation depends on the reaction of NO
and O2, also called NO auto-oxidation
2 NOþO2/2 NO2
NO2þNO/N2O3
and the reaction rate for its formation in water has been
estimated as Rate = k [NO]2 [O2] with k being around 2–5 · 106
M - 2 s - 1, consistent with the rate-limiting formation of NO2
(11, 48, 165). Kinetic models integrating these reactions with
the formation of other RNS have shown that N2O3 formation
would not be very important at the NO concentrations esti-
mated for biological systems (82, 87).
However, two facts can be considered that argue in favor
of the relevance of this mechanism in localized cellular
FIG. 1. Short-range and long-range NO signaling. Clas-
sical NO signaling, such as sGC activation, can be exerted at
a relatively long distance from NO sources (NOS enzymes),
even if NO concentration diminishes while targets are farther
from the NOS. We postulate that S-nitrosylation of target
proteins (TP) is essentially a short-range mechanism, limited
to a tiny sphere around NOS. Among other factors described
in the text, RNS formation requires higher NO concentra-
tions, which are easier to achieve in the NOS surroundings
(this is more clear in interacting proteins, IP), and deni-
trosylases such as Trx or GSNOR with GSH can narrow the
range of action by reducing target protein S-nitrosylation.
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environments. First, the reaction rate is very sensitive to the
concentrations of the reactants, particularly NO. In a cell
system where reactants concentrations are not in equilibrium,
NO concentration would be much higher in a relatively small
virtual sphere surrounding the NOS enzymes, allowing for
faster formation of N2O3 and thiol S-nitrosylation. Second, it
has been shown that in hydrophobic environments such as
biological membranes, the same third-order rate law is ob-
served, but the rate constant is increased up to 300 times (97,
113, 114); even with this rate acceleration, the overall NO fate
would not be affected, but the reaction would be relevant
enough to produce localized nitrosating species in membrane
regions (114), where NOS enzymes localize due to their
membrane binding structures.
An alternative mechanism for S-nitrosylation by nitrogen
oxides involves the thiyl formation by NO2 and subsequent
reaction with NO (76):
NO2þRSH/R-S þNO2 þHþ
NOþR-S/RSNO
Again, the rate limiting step is the formation of NO2, and it
also requires an additional NO molecule, so the same con-
siderations for the localized formation of N2O3 apply to this
mechanism.
Metal-catalyzed formation of nitrosothiols has been de-
scribed, mainly explained by a mechanism involving a one-
electron oxidation of NO by oxidized transition metals, such
as Fe3 + or Cu2 + ; the nitrosonium (NO + ) formed could ni-




This mechanism has been shown to take part in specific
proteins, where it can be considered as an enzymatic ‘‘ni-
trosylase’’ mechanism, such as in auto-nitrosylation of he-
moglobin and other globins, and in S-nitrosoglutathione
(GSNO) formation by ceruloplasmin or cytochrome c (re-
viewed in Refs. 5, 23, 53).
Recently, another pathway for S-nitrosylation formation
has been described that could operate through generation of
dinitrosyl-iron complexes (DNIC) from NO (20), and evidence
has been found that DNIC can be a main form of NO in cells
(62). This pathway will certainly deserve further investigation
to assess the possible physiological role of these complexes as
catalyzers of S-nitrosylation, and to test whether they are
modified by subcellular localization.
Transnitrosylation
The nitroso group can be easily transferred between thiol
groups, in a reversible reaction called transnitrosylation (or
transnitrosation):
RSNOþR¢SH/RSHþR¢SNO
Transnitrosylation among low-molecular-mass (LMM) thiols
and protein thiols has been studied for a long time. LMM
nitrosothiols, and especially GSNO (as the main intracellular
LMM thiol is glutathione) can be considered as putative
S-nitrosylation vectors in cells that could transmit the S-ni-
trosylation signal from the nitrosothiol-producing foci to po-
tential protein targets. A recent study that analyzed the
structural features of confirmed protein S-nitrosylation sites
in the literature has postulated that a subset of proteins and
residues could be specifically transnitrosylated by GSNO
(101). However, the reaction of GSNO with protein thiols is
more complicated, as it can also form a mixed disulfide by
S-glutathionylation (reviewed in Refs. 80, 103, 105, 111), most
probably with formation of nitroxyl (HNO):
PSHþGSNO/PSNOþGSH
PSHþGSNO/PSSGþHNO
Thus it would be interesting to compare the structural fea-
tures regulating the balance between these reactions.
Several groups have recently described transnitrosylation
reactions between proteins. These include protein–protein
interaction determinants as specificity factors, as is the case
in other enzymatic post-translational modifications used in
signal transduction, such as phosphorylation. Each of the
described transnitrosylases may have a restricted or broader
range of target proteins and residues that can be preferentially
S-nitrosylated due to their specific interactions. The nitroso
group is transferred by equilibrium reactions and thus the
thermodynamic comparison between both reactions (which
can also be described with the redox potentials) has also to be
considered. Recent reviews have thoroughly covered protein–
protein transnitrosylation (5, 119), so we will just briefly de-
scribe the most relevant transnitrosylases.
Early studies on S-nitrosylated hemoglobin (SNO-Hb) re-
ported that it was able to release NO to the blood flow causing
an increase in blood pressure (50, 75, 142). Hb presents a heme
group in each of its four subunits with a central iron atom,
where O2 binds. When O2 concentration is low, NO binds to
the iron; by an auto-S-nitrosylation reaction, this NO moiety is
transferred to Cys93, and Hb suffers a conformational change
from relaxed to tense structure. A clue for the export of the NO
moiety came from the description of transnitrosylation from
SNO-Hb to the most abundant protein in red blood cells, the
Anion Exchanger 1 (AE1) (128). SNO-Hb interacts with AE1 in
the erythrocyte membrane, promoting its transnitrosylation;
subsequently the NO moiety leaves AE1 and diffuses into
vessels (128). However, how this NO moiety is transferred
from AE1 protein to vessels remains unclear.
Caspase-3 inactivation by S-nitrosylation of an active site
Cys (Cys163) is reverted during Fas-induced signaling (100).
The thioredoxin (Trx) system was described as a caspase-3
activator by denitrosylation via two different biochemical
mechanisms (112). The first one implies thiol reduction in a
‘‘classical’’ way by means of its two active site Cys (Cys32 and
Cys35) (8, 86). The second one is a transference of the NO
moiety from caspase-3 to Trx by transnitrosylation of Cys32 in
Trx. S-Nitrosylation of nonactive Cys has also been described,
particularly Cys62, Cys69, and Cys73, in conditions where
active site cysteines were oxidized (54, 59, 166). A recent
study, using C32S and C35S mutants, demonstrated that Trx
S-nitrosylated in Cys73 is able to transnitrosylate many cel-
lular targets including caspase-3 (112, 166, 168). Interestingly,
when Trx is S-nitrosylated in Cys73, the disulfide bond in the
active site C32–C35 is not reduced by Trx reductase; both
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enzymes are then uncoupled, which can be a mechanism to
prevent the denitrosylase activity of Trx while promoting its
transnitrosylase activity (59). Figure 2 summarizes the trans-
nitrosylation and denitrosylation mechanisms involved in
caspase-3 activation and inhibition in physiological and stress
conditions.
Recently, S-nitrosylation of XIAP, one of the most impor-
tant caspase-3/7/9 inhibitory proteins, was described in
neurons (120, 155). As a consequence of this nitrosylation, the
E3 ubiquitin ligase activity of XIAP is decreased and caspase
degradation is inhibited, favoring apoptosis. This process is
especially important in neurodegenerative diseases such as
Alzheimer (AD), Parkinson (PD), and Huntington (HD) dis-
eases, where a high content of SNO-XIAP was observed,
suggesting that this reaction contributes to neuronal damage
in these diseases. Interestingly, caspase-3 is able to transni-
trosylate XIAP in pathophysiological situations of nitrosative
stress or excitotoxicity, promoting apoptosis both by the
protease activity of caspase-3 and impairing its degradation
by inhibition of XIAP (120, 155).
In AD, amyloid-b peptide oligomerization provokes an
increase in NO production, which leads to S-nitrosylation of
Cdk5 (132). SNO-Cdk5 transnitrosylates dynamin related
protein 1 (Drp1) in Cys644 (28). This reaction causes a mito-
chondrial fission hyperactivation as well as a compromise in
mitochondrial bioenergetics which, in synaptic structures,
could lead to synaptic loss (28, 159).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is
also implicated in transnitrosylation processes. GAPDH is S-
nitrosylated in its Cys150 residue; S-nitrosylated GAPDH
interacts with Siah1, and it is translocated to the nucleus
due to Siah1 nuclear localization signal (56). Once in the nu-
cleus, SNO-GAPDH transnitrosylates proteins such as SIRT1,
HDAC2, and DNA-PK, affecting metabolic pathways, normal
aging processes, chromatin remodeling in neuronal develop-
ment, or neurodegeneration (81, 121).
Transnitrosylation has been involved in the formation of
pulmonary arterial hypertension (PAH). Mice chronically
treated with N-acetylcysteine (NAC) or its S-nitrosylated
form, S-nitroso-N-acetylcysteine (SNOAC), developed PAH,
mimicking the effects of chronic hypoxia (126). This study
showed that NAC needs to be converted to SNOAC and that
activation of the HIF-dependent hypoxia response through
transnitrosylation of particular proteins in the canonical HIF
activation pathway (such as pVHL) could be among the mo-
lecular mechanisms responsible for this effect (126).
Denitrosylases
Removal of the nitroso group is another important aspect
of S-nitrosylation signaling. It is generally accepted that
S-nitrosylation is a labile modification, and that the levels of
cellular nitrosothiols are low, due to a rapid turnover. Deni-
trosylation was firstly conceived as an unregulated and
spontaneous process, and several nonenzymatic mechanisms
of denitrosylation have been described that could potentially
act in vivo. These include reactions mediated by nucleophilic
compounds, transition metal ions, reactive oxygen species
(ROS), and ascorbate (reviewed in Ref. 147).
Accumulating evidence shows that several enzymes can
catalyze denitrosylation in vitro (14, 64, 77, 143, 154) and
in vivo (16, 95) (reviewed in Refs. 5, 17). These enzymes may
contribute to spacially limit the action of S-nitrosylation
events, helping to keep their precise subcellular localization
close to NO sources. They also may help to protect cells
from ‘‘excessive’’ S-nitrosylation, as, for example, when
inducible nitric oxide synthase (iNOS) is induced in im-
mune cells in order to attack pathogens (reviewed in Ref.
60). In addition, they provide another mechanism of spec-
ificity and regulation since these enzymes may act over
defined sets of substrate proteins. This is more important in
examples of tightly regulated denitrosylation that may ac-
tivate precise signals, such as the case of Fas-induced cas-
pase-3 denitrosylation (100), which can be mediated by Trx
(16), or receptor-regulated endothelial nitric oxide synthase
(eNOS) activation (37).
Two main enzymatic mechanisms of denitrosylation
have emerged in recent studies, GSNO reductase and the
thioredoxin system. GSNO reductase (GSNOR) is an evolu-
tionary conserved enzyme system previously known as al-
cohol dehydrogenase class III. GSH can react with a protein
nitrosothiol leading to either transnitrosylation and subse-
quent generation of S-nitrosoglutathione (GSNO) or glu-
tathionylation of the protein, in both cases with subsequent
FIG. 2. Summary of trans-
nitrosylation reactions be-
tween Trx, caspase-3, and
XIAP that leads to caspase-3
activity regulation, including
Cys residues that undergo S-
nitrosylation. The active site of
Trx denitrosylases caspase-3 in
normal conditions, producing
HNO and its own disulfide,
which is reduced back by Trx
reductase (TR). When its active
site Cys is oxidized, Trx S-
nitrosylated in Cys73 is able to
transnitrosylate caspase-3 in
Cys163. S-nitrosylated caspase-
3 may also transnitrosylate its
inhibitor XIAP, leading to a
release of caspase-3.
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release of the NO group from the protein thiol. This is
supported by the observation that addition of GSH to SNO-
proteins leads to their denitrosylation (125). GSNOR mainly
catalyzes the denitrosylation of GSNO towards GSSG, uti-
lizing NADH as an electron donor. The cycle is completed as
GSSG is reduced by glutathione reductase and NADPH. Al-
though GSNOR does not directly act on protein nitrosothiols,
an equilibrium between GSNO and SNO-proteins is main-
tained by transnitrosylation, since GSNOR-knockout mice
showed increased levels of both GSNO and SNO-proteins
after nitrosothiol addition or lipopolysaccharide (LPS) treat-
ment (95, 96).
GSNOR participates in signal transduction through G
protein-coupled receptors (GPCRs) and, in particular, b2-
adrenergic receptor (b2-AR). Upon agonist stimulation, GPCR
kinases (GRKs) 2 and 3 are recruited to the plasma membrane
by interaction with Gbc subunits and phosphorylate the b2-
AR at the cytoplasmic tail (Fig. 3). This allows b-arrestin 2 to
be transiently recruited by the activated receptor and driven
to clathrin-coated pits where, after its dissociation, the re-
ceptor internalizes and becomes desensitized (reviewed in
Ref. 135). Both GRK2 and b-arrestin 2 S-nitrosylations are
controlled by GSNOR since both augment in GSNOR-
knockout mice. S-Nitrosylation at GRK2 Cys340 decreased its
kinase activity, b-arrestin 2 interaction and b2-AR internaliza-
tion and desensitization (164). On the other hand, binding of
b-arrestin 2 to the clathrin pit is promoted by S-nitrosylation,
which in turn increases b2-AR internalization (123). This dif-
ferential regulation of GPCR signaling by S-nitrosylation
suggests that local denitrosylation of particular elements be-
comes important for cell signaling. GSNOR has been linked
with the development and protection against several diseases.
S-Nitrosylation of O6-alkylguanine-DNA alkyl transferase
(AGT) in the liver of GSNOR - / - mice after LPS or diethylni-
trosamine treatment promoted decreased capability of DNA
repair, thus increasing hepatocellular carcinoma incidence
(162). On the other hand, GSNOR deficiency protected against
myocardial infarction (89).
The other best known denitrosylase is the thioredoxin (Trx)
system. While GSNOR denitrosylates SNO-proteins indi-
rectly through GSNO formation, Trx system has been shown
to denitrosylate them directly. As mentioned above, un-
coupled Trx can act as a transnitrosylase when its Cys73 is
S-nitrosylated, after disulfide formation between catalytic
Cys32 and Cys35; however, for its denitrosylase function it
uses the catalytic center with both Cys32 and Cys35 in their
reduced state (167). Trx establishes a disulfide bridge with the
substrate SNO-protein allowing the release of the NO (in the
form of HNO) (16). An intramolecular disulfide bond is then
formed between Cys32 and Cys35, substituting the intermo-
lecular disulfide. Thioredoxin reductase (TR) is in charge of
restoring the reduced state of these Cys through a NADPH–
dependent reduction of the Trx intramolecular disulfide.
Trx1 was identified as the caspase-3 constitutive and cy-
tosolic denitrosylase since inhibition of Trx1 or TR1 produced
increased amounts of SNO-caspase-3 (16). On the other hand,
Trx2 was identified as a denitrosylase of mitochondrial cas-
pase-3 upon Fas ligand stimulation, a process required for its
activation and, therefore, for apoptotic cell death (16). Fur-
thermore, the Trx-interacting protein (Txnip) has been shown
to inhibit denitrosylate activity of Trx, since it increases SNO-
protein levels (43).
Proteomic analyses have helped to highlight Trx as a de-
nitrosylase. In cytokine-activated macrophages where iNOS
is induced, we used a ‘‘fluorescence switch’’ technique to label
S-nitrosylated proteins, identifying eleven proteins that were
differentially S-nitrosylated when the thioredoxin reductase
was inhibited with auranofin (152). Benhar et al. used a
quantitative LC-MS/MS approach to identify proteins that
were denitrosylated when they added Trx/TR to cell extracts
that had been nitrosylated in vitro (18). Interestingly, Trx
targets of transnitrosylase activity could be differentiated
from those of denitrosylation, providing specificity to the
search of Trx substrates in the context of S-nitrosylation (168).
Denitrosylation has emerged as a relevant mechanism by
which functional relevance of S-nitrosylation is regulated.
FIG. 3. Agonist-stimulated




separation of a from b and
c subunits of the G protein.
The two latter subunits
bind reduced GRK2, which
phosphorylates b2-AR. S-
Nitrosylation of GRK2 pre-
vents its binding to b and c
subunits. Once phosphory-
lated, b2-AR recruits b-arrestin
which becomes S-nitrosylated
and subsequently binds to
AP2 and clathrin, thus allow-
ing internalization. If b-
arrestin is not S-nitrosylated,
internalization of b2-AR be-
comes attenuated.
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Study of the dynamic equilibrium between nitrosothiol gen-
eration and its removal, as well as the enzymes implicated
will provide more accurate knowledge of S-nitrosylation
regulation in vivo and their connection with diseases.
Regulation of S-Nitrosylation by Subcellular
Localization of eNOS
Despite some evidence indicating a possible role for the
compartmentalization of iNOS and short-range actions of
high levels of NO in protein S-nitrosylation—for instance, in
the S-nitrosylation of matrix metalloproteinase 9 (MMP-9) at
the leading edge of migrating cells, and chloride intracellular
channel 4 (CLIC4) during its nuclear translocation in macro-
phages (58, 99)—eNOS and neuronal nitric oxide synthase
(nNOS) are the prototypic NOS whose dependence between
localization and S-nitrosylation has been more extensively
studied (70, 151).
In cells, eNOS traffics between the plasma membrane and
the cytoplasmic face of the Golgi apparatus by means of both
specific interaction with proteins involved in vesicle traf-
ficking and a cycle of palmitoylation/depalmitoylation on
Cys15/Cys26, two amino acid residues whose mutations do
not affect the catalytic activity of the enzyme itself but de-
crease NO production in cells due to alteration of eNOS lo-
calization (36, 94, 122, 146). A large body of work indicates
that the confinement of eNOS in cell compartments and its
proximity or binding to target proteins may lead to selective
S-nitrosylation.
eNOS at the plasma membrane
Several studies have shown that preferential localization of
eNOS at the plasma membrane produces higher levels of NO
and S-nitrosylation in this region than in the Golgi apparatus.
At the plasma membrane, eNOS is retained in its low active
state associated to caveolin-1 in caveolae, and it is fully acti-
vated after dissociation from caveolin-1 by Ca2 +/calmodulin
binding and kinase-mediated phosphorylation on key serine
residues (Ser1177, Ser635, and Ser617); among them, phos-
phorylation of Ser1177 by Akt is particularly remarkable as
the most constant sign of eNOS activation (36, 46). In contrast,
the association of eNOS with the actin cytoskeleton by means
of its interaction with NOS-interacting protein (NOSIP) or its
trafficking towards the Golgi complex by binding to NOS
traffic inducer (NOSTRIN) can reduce eNOS activity, moving
the enzyme away from plasma membrane-associated signals
of activation (122). eNOS activity can also be negatively reg-
ulated through auto-S-nitrosylation on Cys94 and Cys99, a
negative feedback mechanism that affects NO synthesis by
impairing substrate binding and/or electron transfer at the
eNOS dimeric interface (36). Studies carried out with both
plasma membrane-restricted eNOS and a cytoplasmic mutant
deficient in myristoylation on Gly2—which alters its mem-
brane binding and inhibits further palmitoylation—clearly
show that membrane localization is required for S-nitrosylation
(37, 38). Since eNOS can be reversibly S-nitrosylated, com-
partmentalized S-nitrosylation of eNOS might be favored, for
instance, by environments devoid of denitrosylases such as
thioredoxin or GSNOR. However, complementary studies
carried out with compartment-targeted iNOS constructs
and calcium-independent eNOS showed no differences be-
tween the activities of these mutants irrespectively of their
subcellular localization (32, 72, 131), suggesting that the lev-
els of NO produced are the most important factors for lo-
calized S-nitrosylation and that, in the case of constitutive/
regulatable NOS, proximity to the upstream signaling
pathways—Ca2 +/calmodulin and Ser/Thr kinases—may
explain the differences in NO production and S-nitrosylation
observed between membrane cell compartments.
In addition to auto-S-nitrosylation of eNOS, other proteins
involved in what can be called the ‘‘eNOS system’’ are targets
of S-nitrosylation, which can alter the system activity. The
eNOS-binding protein caveolin-1 is constitutively S-ni-
trosylated in endothelial cells (117), although if this can reg-
ulate eNOS localization and activity has not been described,
to our knowledge. The chaperone Hsp90 also interacts with
eNOS, increasing its affinity for calmodulin and Akt, and thus
its activity (51, 149). We have shown that Hsp90 can be
S-nitrosylated in Cys597 (107), an amino acid residue located
in the region of interaction with eNOS (40). This modification
inhibits the ATPase activity of Hsp90, and its ability to acti-
vate eNOS, representing an additional S-nitrosylation-based
feedback mechanism modulating eNOS activity. It is worth
noting that the binding of Hsp90 to NOS is not an exclusive
hallmark of eNOS since both nNOS and iNOS can also be
activated by binding to Hsp90 (129, 169). Whether nNOS
and/or iNOS may also S-nitrosylate Hsp90 in the context of a
negative regulatory feedback loop of NOS activation, and
whether their subcellular localization is actually important for
Hsp90 S-nitrosylation deserves further research.
An increasing number of proteins S-nitrosylated by eNOS
at the plasma membrane have been identified over the last
years. eNOS can interact with the GTPase dynamin-2, in-
creasing receptor-mediated endocytosis through S-nitrosylation
of Cys607, a modification that fosters dynamin oligomeriza-
tion and GTPase-dependent vesicle scission from the plasma
membrane (25, 158). Interestingly, a recent report suggested a
role for eNOS and dynamin-2 in the immune-escape of ur-
opathogenic strains of Escherichia coli (161). The study shows
that E. coli invasion of bladder epithelial cells in recurrent
urinary tract infections is facilitated by endocytosis mediated
by eNOS-dependent S-nitrosylation of dynamin-2. It would
be important to address if this is a general mechanism of es-
cape for those microorganisms infecting hosts through NO-
producing specialized barriers. b-Arrestin is also regulated by
eNOS-dependent S-nitrosylation; it forms a complex with
eNOS that translocates to GPCRs upon agonist binding, re-
sulting in eNOS activation and b-arrestin S-nitrosylation
(123). Once b-arrestin is S-nitrosylated, eNOS dissociates from
the complex, and stimulated GPCRs can internalize by asso-
ciation with the clathrin-b-arrestin endocytic machinery (123).
b-Catenin, an essential component of adherens junctions—
intercellular structures controlling permeability on epithelial
and endothelial monolayers—is also a target of S-nitrosylation
by eNOS. Stimulation of endothelial cells with VEGF induces
eNOS-dependent S-nitrosylation of b-catenin on Cys619, an
important amino acid residue for the interaction with VE-
cadherin and the preservation of the permeability cell barrier
(153). Up to our knowledge, it is not clear yet if there is a direct
interaction between eNOS and b-catenin. H-Ras, a Ras iso-
form localized both at the plasma membrane and the Golgi
complex, has recently been added to the list of proteins that
can be activated at the plasma membrane by eNOS-dependent
S-nitrosylation. In endothelial cells, bradykinin stimulation
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induces preferential activation of H-Ras at the plasma mem-
brane through a mechanism independent of Src activation
which involves S-nitrosylation of H-Ras on Cys118 (15).
N-Ethylmaleimide-sensitive fusion protein (NSF), a SNARE
regulator involved in vesicular trafficking and exocytosis of
platelet a-granules and Weibel-Palade bodies from endothe-
lial cells, is also S-nitrosylated by eNOS as demonstrated
using NOS inhibitors and eNOS-deficient cells (109, 116).
S-Nitrosylation of NSF reduces granule exocytosis by stabi-
lizing SNARE complexes in vesicles. The possible role played
by the compartmentalized activity of eNOS on NSF S-
nitrosylation has been studied, trying to discriminate the ef-
fects of Golgi and plasma membrane localization. Whereas a
recent study with eNOS directed to either plasma membrane
or Golgi found that eNOS induces higher levels of NSF
S-nitrosylation at the plasma membrane (131), imaging anal-
ysis from previous studies carried out with wild-type eNOS-
transfected COS-7 cells clearly showed that in response to
ATP eNOS produced NO mainly on the Golgi complex, a
compartment in which most of eNOS and S-nitrosylated
proteins are concentrated (71). In this regard, NSF trafficking
may play an important role in a cellular model of pulmonary
arterial hypertension induced with the pirrolizidine alkaloid
MCTP, which induces megalocytosis of pulmonary arterial
endothelial cells (117, 118). These studies show that MCTP
disrupts vesicular trafficking in endothelial cells, mislocaliz-
ing eNOS in the cytoplasm accompanied by loss of NO from
caveolae and reduced S-nitrosylation and localization of NSF
on the Golgi. Whether reduced NSF S-nitrosylation in MCTP-
induced aberrant trafficking is the consequence of eNOS
dysfunction at the plasma membrane, the Golgi complex, or
both remains an open question.
eNOS on the Golgi
Several studies have also shown that eNOS localiza-
tion on the Golgi complex is functional and contributes to
S-nitrosylation of Golgi-localized proteins (70). Although the
mechanisms involved in eNOS localization on the Golgi
complex are not fully understood, it is clear that palmitoyla-
tion on Cys15/Cys26 and NOSTRIN binding to eNOS play an
important role. In this regard, a recent study shows that ac-
tivation of the transcription factor STAT-3 by the adhesion
molecule PCAM-1 induces NOSTRIN expression and the
traffic of eNOS from the plasma membrane towards the Golgi
complex (110). The role of subcellular localization on eNOS
activation has been studied by transfecting protein versions
with different localization signals. Transfection in COS-7 cells
showed that cis-Golgi-targeted eNOS was less sensitive to
activation by Ca2 + /calmodulin but more easily activated by
Akt-mediated phosphorylation on Ser1179, when compared
to the protein localized on the plasma membrane (45). Similar
cell transfection studies performed in eNOS-deficient endo-
thelial cells showed that on the Golgi complex eNOS may also
result less sensitive to Akt activation but resistant to choles-
terol and LDL inhibition, releasing lower amounts of NO than
at the plasma membrane (170). Altogether, these reports
suggest that compartmentalized activity of eNOS on the Golgi
complex may be cell-type specific and/or that low to mod-
erate levels of NO would be enough to S-nitrosylate Golgi
resident proteins near eNOS, either due to an enhanced se-
lectivity for S-nitrosylation, or to decreased denitrosylation.
A recent proteomic study combining biotin-switch assay
and mass spectrometry has identified nine Golgi-resident
proteins S-nitrosylated in Golgi membranes isolated from
rat livers (136). Among those, the authors focused on the
study of extracellular matrix metalloproteinase inducer
(EMPRIN)—a member of the immunoglobulin superfamily
involved in invasion and metastasis—and Golgi phospho-
protein 3 (GOLPH3), a potential oncogene involved in protein
glycosylation and mTOR regulation. Both proteins interacted
with eNOS and co-localized with it on the Golgi of endothe-
lial cells, increasing their S-nitrosylation upon activation
with the Ca2 + ionophore ionomycin and also in pathophysi-
ological conditions such as cirrhosis (136).
In T cells, S-nitrosylation is mainly compartmentalized
near the Golgi complex, where active eNOS localizes. In this
compartment, eNOS S-nitrosylates N-Ras at Cys118, fostering
the conversion of GDP- to GTP-bound N-Ras, and the con-
sequent activation of the MAPKs ERK-1 and ERK-2 (67). In-
terestingly, although T cells express both K-Ras and N-Ras
(which share the same conserved Cys residue sensitive to
S-nitrosylation), only N-Ras becomes S-nitrosylated due to its
preferential localization on the Golgi, suggesting that prox-
imity of eNOS-derived NO to N-Ras is an important deter-
minant of S-nitrosylation and MAPK activation (Fig. 4).
MAPK phosphatase 7 (MKP7)—a negative regulator of the
MAPK JNK3—is S-nitrosylated by eNOS on Cys244 in re-
sponse to SDF-1, a CXC chemokine with proangiogenic
properties on endothelial cells (130). S-Nitrosylation reduces
the phosphatase activity of MKP7, increasing JNK3 activity,
and thus endothelial cell migration. Although there is no ev-
idence of compartmentalized S-nitrosylation of MKP7, since
the Golgi complex plays an important role in the regulation
of MAPK pathways (19), it would be interesting to explore
whether eNOS-mediated MKP7 S-nitrosylation may take
place on the Golgi.
Nitric Oxide Synthases and the Heart:
Role of Localized S-Nitrosylation
Very early since the characterization of eNOS in endothelial
cells, it was clear that this isoform was expressed in cardio-
myocytes and that NO could play a role as a regulator of
cardiac rhythm and inotropic responses (108, 139). It is now
accepted that the heart expresses both eNOS and nNOS, the
former in endothelial and endocardial cells, the latter in ner-
vous tissue and autonomic ganglia, and both in cardiomyo-
cytes. In addition, iNOS may be expressed upon exposure of
endothelial cells or cardiomyocytes to cytokines or proin-
flammatory stimuli (9, 12). A significant discovery which
shifted the view of the role of NO in the heart was related to
the topological confinement of NO signaling, whereby eNOS,
localized in caveolae, mainly directed its action towards the
inhibition of b-adrenergic-induced inotropy. In contrast,
nNOS, which is targeted to sarcoplasmic reticulum, stimu-
lates calcium release via the ryanodine receptor (RyR) with
an opposite effect on contractility (13). Both classical and
nonclassical modes of signaling (103) have been demon-
strated for NO within the heart. The classical cGMP-mediated
pathway is responsible for several important actions of NO
related to regulation of contractility and inhibition of cardiac
remodeling (see Ref. 55 for review). Elevation of cGMP levels
encompasses the activation of cGMP-dependent protein
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kinases (PKGs) that are important for the regulation of con-
tractility through the inhibition of the L-type Ca2 + channel
(LTCC). Noteworthy, cGMP signaling in cardiomyocytes is
also compartmentalized due to specific subcellular locali-
zation of soluble and particulate guanylate cyclases and of
phosphodiesterase enzymes (PDEs), thus offering another
example of subcellular localization as a major means to
control intracellular signaling. The nonclassical pathway is
inherently related to NO-induced post-translational modifi-
cations of thiols, such as S-nitrosylation and S-glutathionyla-
tion (103, 105, 106). For a comprehensive update on the role of
these PTMs in the cardiovascular system, the readers may
wish to consult recent excellent reviews (102, 138).
eNOS has been shown to localize mainly within the ca-
veolae of sarcolemma and T-tubules, which supports the idea
that NO generated through this isoform exerts its action on
vicinal cell surface receptors that regulate contractility, in-
cluding muscarinic, b-adrenergic, and bradykinin receptors
(57). The global eNOS effect is negative on chronotropy and
inotropy and is counteracted by the action of nNOS, circum-
scribed to the sarcoplasmic reticulum. Interactions of eNOS
and nNOS with other proteins sharing their subcellular lo-
calization, caveolin 3 and the RyR, respectively, are essential
to understanding their action on cardiac function (156).
S-Nitrosylation has been described to involve several proteins
regulating contractility including LTCC, RyR, Kv1.5 channel,
and sarcoplasmic/endoplasmic reticulum Ca2 + -activated
ATPase (SERCA). The ryanodine receptor Ca2 + release
channel (RyR2), together with SERCA2a, are critical compo-
nents of the excitation–contraction coupling molecular ma-
chinery. It has been proposed that the close apposition of
nNOS and RyR2 facilitates S-nitrosylation of the latter, in-
creasing its channel opening probability (88). A similar
mechanism may operate for the S-nitrosylation-induced reg-
ulation of LTCC and SERCA2a which has also been shown to
become activated by NO-induced S-glutathionylation (3).
A deficit of nNOS-mediated S-nitrosylation of RyR2 has
been associated with pathological cardiac responses such as
arrhythmia (49). Other ion channels have also been proposed
to undergo S-nitrosylation: intermediate conductance potas-
sium channel (IK1), late inward Na + current (InaL), slowly
activating delayed rectifier current (Iks), and ATP-sensitive
K + channel (see Ref. 150 for review). Finally, eNOS and vic-
inal scaffolding proteins are themselves potential targets for S-
nitrosylation, at least in endothelial cells (37, 107), resulting in
an autoinhibitory feedback mechanism. Thus, knowledge of
FIG. 4. Compartmentalized S-nitrosylation of N-Ras but not K-Ras in antigen-stimulated T cells. The figure represents
the signaling pathways involved in the selective eNOS-dependent S-nitrosylation and activation of N-Ras on the Golgi
complex. Although K- and N-Ras are both farnesylated, K-Ras is targeted to the plasma membrane (PM) by means of a basic
carboxyl-terminal region of amino acids, whereas N-Ras is mainly localized on the Golgi by palmitoylation, co-localizing
with eNOS. Upon TCR binding to antigen (Ag) on an antigen presenting cell (APC), the TCR complex is phosphorylated on
the CD3n chains, which induces the activation of PLC-c and Akt by recruitment of the tyrosine kinase ZAP-70. PLC-c
increases the cytosolic levels of inositol 1,4,5-triphosphate, releasing Ca2 + from internal stores, which in turn can bind
calmodulin-associated eNOS. On the other hand, Akt can phosphorylate eNOS on Ser1177. As a result of the combined
actions of Ca2 + and phosphorylation, eNOS is activated producing NO on the Golgi, fostering N-Ras activation by
S-nitrosylation on Cys118, an amino acid residue shared by K-Ras but which is not S-nitrosylated in T cells due to K-Ras
localization at a different cell compartment.
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S-nitrosylation modification of cardiac function depicts a
complex scenario which still awaits further clarification
through the employment of animal models and corroboration
by clinical settings where this PTM is specifically addressed.
Short-Range S-Nitrosylation Signaling in the Brain
In neurons, NO is produced essentially by neuronal NO
synthase (nNOS), which can be localized in well-defined
neuronal localizations, such as the presynaptic terminal or the
postsynaptic density, where NO production can be coupled to
synaptic transmission, either in an anterograde or retrograde
manner. The best characterized signaling molecule coupled
to NO production by nNOS in the brain is the neurotrans-
mitter glutamate. Glutamate is the main excitatory neuro-
transmitter in the central nervous system, and is recognized
by both ionotropic and metabotropic receptors. The calcium-
permeable ionotropic N-methyl-D-aspartate (NMDA) re-
ceptor was shown to be associated to glutamate-induced
calcium-dependent NO production by nNOS in the brain (21,
47). NMDA receptors are also central to neurodevelopment,
synaptic plasticity, and neurodegeneration. Other ionotropic
glutamate receptors have also been involved in these pro-
cesses, such as AMPA receptors. Overactivation of glutamate
receptors often results in excitotoxicity, a phenomenon caused
by excitatory neurotransmitters that cause a rise in the intra-
cellular calcium concentration induced by receptor activation,
which may trigger cell death pathways (2, 41, 84).
NMDA receptor coupling to nNOS by PSD-95:
Implications for neuronal survival
The participation of NMDA receptors in excitotoxic neu-
ronal death has been extensively studied in the last 30 years,
and NO has been shown to be a participant in this complex
cascade of events. Glutamate release by synapses causes an
increase in the intracellular calcium concentration of the
postsynaptic neurons, and this rise in calcium is usually me-
diated by influx through voltage-dependent calcium chan-
nels, influx by calcium-permeable receptors (such as NMDA
or certain types of AMPA receptors) or by reversal of the
sodium–calcium exchanger (10). Activation of NMDA re-
ceptors by glutamate causes an influx of calcium through the
receptor itself that was shown to be linked to the activation of
nNOS and neuronal death (22). Activation of AMPA receptors
was also linked to NO production by nNOS, resulting in
neurotoxicity (6). NO produced by nNOS following activation
of NMDA receptors was initially shown to mediate the neu-
rotoxicity of glutamate in cultured neurons (34), and a num-
ber of studies later showed that NO produced by nNOS
during a variety of brain insults is responsible, at least par-
tially, for the neuronal damage (for review, see Refs. 2, 7, 24,
27, 78, 84).
NO is produced rapidly following stimulation of NMDA
receptor, which prompted the investigation of whether a
structural proximity between this glutamate receptor and
nNOS existed. The PDZ domains in PSD-95 mediate a struc-
tural interaction between the NMDA receptor NR2 subunits
and nNOS at the postsynaptic density (31), an area that is rich
in anchoring and scaffolding proteins that help in making
synaptic transmission more efficient (Fig. 5). Another study
showed that uncoupling the NMDA receptor from nNOS by
interfering with PSD-95 resulted in loss of the neurotoxic ef-
fect of NO (137), without loss of calcium influx through the
receptor. Peptide inhibitors such as Tat-NR2B9c that disrupt
the coupling of the NR2 subunits of the NMDA receptor and
PSD-95 provoke a loss of NO production following NMDA
receptor activation (1). Such peptide inhibitors contain a se-
quence similar to the C-terminal of NR2 subunits, which
competes with native NMDA receptors and disrupts the in-
teraction of NMDA receptors and PSD-95.
PSD-95 itself presents sites of competing regulation
which control the targeting of PSD-95 to the postsynaptic
density, on Cys3 and Cys5, which can be both regulated by
S-palmitoylation (increases the localization of PSD-95 at
the postsynaptic density) or by S-nitrosylation (reduces the
clustering of PSD-95 on synapses), supporting a model for
regulation of NMDA receptor activation coupled to NO
FIG. 5. Postsynaptic localization of nNOS and S-
nitrosylation signaling in a glutamatergic synapse. Produc-
tion of NO by nNOS following glutamate release is coupled
to activation of Ca2 + -permeable NMDA receptors (NMDAr),
which are anchored at the postsynaptic density by scaffold-
ing proteins, including PSD-95. PSD-95 binds to NMDAr and
nNOS via PDZ domains, allowing for a close proximity of
permeable NMDAr and nNOS. NO produced in close
proximity to NMDA receptors triggers the S-nitrosylation
of NR2A subunits (SNO-NR2A), which then allow less Ca2 +
in. Activation of NMDAr also triggers the recruitment of
more AMPA receptors (AMPAr) towards the membrane
surface. S-Nitrosylation of stargazin (SNO-stargazin) and
NSF (SNO-NSF) contributes to increase the surface expres-
sion of AMPAr during events of synaptic plasticity following
the activation of NMDAr. On the other hand, S-nitrosylation
of PICK1 facilitates its release from AMPAr after membrane
insertion and also facilitates surface expression of AMPAr.
When these proteins are out of range of NO and are not
S-nitrosylated, PICK1 interacts more strongly with the re-
ceptor while NSF interacts more weakly, allowing the
binding of proteins that facilitate endocytosis of AMPAr.
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production via PSD-95, by controlling the postsynaptic lo-
calization of PSD-95 as well (63).
The close proximity of nNOS and the NMDA receptor
via PSD-95 in the postsynaptic density facilitates the regula-
tory effect of NO also on the NMDA receptor itself (29). The
first reports that NO would affect redox modulatory sites of
the NMDA receptor date back to the 1990s (85, 91, 93). It was
then hypothesized that S-nitrosylation would decrease the
permeability of the receptor, as a neuroprotective feedback
mechanism (92) (Fig. 5). Site-directed mutagenesis studies
later identified Cys399 in the NR2A subunit of the NMDA
receptor that may undergo endogenous S-nitrosylation and
thus regulate the ion channel activity, decreasing calcium in-
flux (30, 79). S-Nitrosylation of NR1 subunits may also occur
on Cys744/Cys798 pair, particularly during hypoxia or stroke
conditions (148), which supports a function for S-nitrosylation
of the NMDA receptor as a way to regulate calcium influx
through the receptor and limit neurotoxicity.
Interestingly, it has been known for a long time that nNOS-
positive neurons are relatively resistant to excitotoxic stimuli
and are spared in several neurodegenerative conditions, such
as Alzheimer disease (66) and Huntington disease (HD) (39).
The selective resistance of nNOS-positive striatal interneurons
in HD was correlated with the fact that such neurons probably
have endogenous S-nitrosylation of their NMDA receptors,
thus becoming less permeable to calcium influx and therefore
less likely to degenerate (171). On the other hand, unlike
nNOS-positive interneurons, striatal medium spiny neurons
do not produce NO and are sensitive to excitotoxic damage
and degenerate more easily. This may render the NMDA re-
ceptor in medium spiny neurons more permeable to calcium,
and thus increase their susceptibility to injury. Furthermore,
in a model of HD, it was observed that PSD-95 and nNOS are
less present in association with the synaptic membrane and
the NMDA receptor in striatal neurons (74), which suggests a
decreased coupling between the receptor and NO production.
S-Nitrosylation and synaptic plasticity
Synaptic plasticity underlies the formation of new memo-
ries and learning processes. One form of synaptic plasticity
is the insertion of synaptic AMPA receptors in postsynaptic
sites following activation of NMDA receptors. The increase in
AMPA receptors at the synapse makes the synapse respond
with larger excitatory currents upon synaptic stimulation,
thus making the synapse stronger. Several intracellular pro-
teins are involved in the recruitment of AMPA receptors
to the synaptic membrane, and some may be functionally
S-nitrosylated (4, 115, 151).
Upon glutamatergic stimulation, AMPA receptors mediate
the initial membrane depolarization that allows activation of
NMDA receptors. Activation of NMDA receptors triggers a
set of events that result in long-term changes in the number of
AMPA receptors present in the synaptic membrane (98).
Following activation of NMDA receptors, a number of pro-
teins are responsible for regulating the insertion or removal of
AMPA receptors to the membrane. NSF and Protein Inter-
acting with C Kinase (PICK1) are two regulatory proteins that
interact with AMPA receptors and that are sensitive to S-ni-
trosylation (Fig. 5). NSF is important for membrane fusion
during exocytosis and was shown to be S-nitrosylated (65). In
this study, the authors show that S-nitrosylation of Cys91
increases the association of NSF with GluR2-containing
AMPA receptors, thus driving surface expression of AMPA
receptors (65). Nitrosylation of NSF was later shown to allow
unclustering of PICK1 and delivery of AMPA receptors to the
membrane (144). This mechanism may be responsible for
long-term potentiation dependent on activation of the NMDA
receptor. Stargazin is another protein important for regulation
of AMPA receptor surface expression, and physiological S-
nitrosylation of stargazin at Cys302 in the C-terminal tail eli-
cited by NMDA receptor activation was shown to increase the
presence of AMPA receptors at the membrane surface (140)
(Fig. 5). Interestingly, the uncoupling of NMDA-PSD-95 in-
teraction with Tat-NR2B9c was shown to affect plasticity re-
lated to nociceptive signaling (33), but a similar approach was
not yet described for synaptic plasticity. To date, of the many
proteins involved in regulating AMPA receptor surface ex-
pression, only NSF, PICK1, and stargazin were shown to be
functionally modified by S-nitrosylation following NMDA
receptor activation and postsynaptic NO production by
nNOS, but possibly other proteins may also be controlled by
S-nitrosylation with implications for synaptic plasticity.
Conclusions
Protein S-nitrosylation is generally accepted as a nonclas-
sical mechanism of NO signaling. Although the precise
biochemical pathways leading to its formation are not com-
pletely understood, several of the pathways that have been so
far described point out to the hypothesis that this modification
is mainly localized close to the NO producing foci, which in
FIG. 6. Integration of several factors affecting short-range
S-nitrosylation signaling. The short-range S-nitrosylation
signaling range of action shadowed in gray (see also Fig. 1)
becomes more complex when other factors are included. In
addition to catalyzed RNS formation that could be exerted
by membranes (not shown), some metal proteins are also
catalyzers of S-nitrosylation formation, expanding the range
of action. Transnitrosylases (including Trx) and other LMM
vectors such as GSNO or DNIC can also selectively extend it
to their targets. On the other hand, denitrosylases such as Trx
or GSNOR, limit the influence of S-nitrosylation in certain
areas and/or in certain protein targets.
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mammals are mainly the NOS enzymes. Examples of sub-
cellular compartmentalization of S-nitrosylation signaling
have been described in neurons and cardiac tissue, where
S-nitrosylated proteins with signaling functions co-localize
with the different NOS isoforms. Similarly, in cells such
as endothelial cells or T lymphocytes, eNOS-dependent S-
nitrosylation is observed in proteins localized at the plasma
membrane or on the Golgi, associated to regulated localiza-
tion and activity of eNOS in these compartments.
A simple model of the short-range signaling exerted by
S-nitrosylation in the NOS proximity is illustrated in Figure 1,
where S-nitrosylation signaling is depicted in a limited
spherical space around NOS. However, consideration of
some of the mechanisms involved in S-nitrosothiol forma-
tion and breakage leads to a more complex picture, in which
S-nitrosylation catalyzers (e.g., specific metal centers, mem-
branes) or S-nitrosylation vectors (such as DNIC, transni-
trosylases) could promote the expansion of the S-nitrosylation
range of action, while the presence of denitrosylases could
restrict it (Fig. 6).
Future studies will confirm, modify or even refute this
hypothesis, but we consider that the subcellular localization
of protein S-nitrosylation needs to be taken into account when
the functional role of this modification is studied. This is im-
portant also in proteomic studies that attempt to identify the
S-nitrosoproteome, even though it poses an additional chal-
lenge to current methodologies.
Acknowledgments
The research in our laboratories is financed by Spanish
Government Grants CSD2007-00020 (RosasNet, Consolider-
Ingenio 2010 programme; to SL and AM-R), CP07/00143
(Miguel Servet programme) and PS09/00101 (to AM-R),
SAF2009-7520 (to SL) and PI10/02136 (to JMS); by Spanish-
Portuguese Integrated Action Grant PRI-AIBPT-2011-1015/E-
10/12 (to AM-R and IMA); by grants from the Foundation for
Science and Technology (FCT, Portugal), COMPETE and
FEDER (Grants PTDC/SAU-NEU/102612/2008, PTDC/
SAU-NMC/112183/2009, PEst-OE/EQB/LA0023/2011; to
IMA); and by the COST action BM1005 (ENOG: European
Network on Gasotransmitters).
Author Disclosure Statement
No competing financial interests exist.
References
1. Aarts M, Liu Y, Liu L, Besshoh S, Arundine M, Gurd JW,
Wang YT, Salter MW, and Tymianski M. Treatment of is-
chemic brain damage by perturbing NMDA receptor- PSD-
95 protein interactions. Science 298: 846–850, 2002.
2. Aarts MM, and Tymianski M. Molecular mechanisms un-
derlying specificity of excitotoxic signaling in neurons. Curr
Mol Med 4: 137–147, 2004.
3. Adachi T, Weisbrod RM, Pimentel DR, Ying J, Sharov VS,
Schoneich C, and Cohen RA. S-glutathiolation by perox-
ynitrite activates SERCA during arterial relaxation by nitric
oxide. Nat Med 10: 1200–1207, 2004.
4. Ahern GP, Klyachko VA, and Jackson MB. cGMP and
S-nitrosylation: Two routes for modulation of neuronal
excitability by NO. Trends Neurosci 25: 510–517, 2002.
5. Anand P, and Stamler JS. Enzymatic mechanisms regulat-
ing protein S-nitrosylation: Implications in health and dis-
ease. J Mol Med (Berl) 90: 233–244, 2012.
6. Araújo IM, Ambrósio AF, Leal EC, Santos PF, Carvalho AP,
and Carvalho CM. Neuronal nitric oxide synthase prote-
olysis limits the involvement of nitric oxide in kainate-
induced neurotoxicity in hippocampal neurons. J Neurochem
85: 791–800, 2003.
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A, Ibiza S, Serrador JM, and Martı́nez-Ruiz A. Nitrosothiols
in the immune system: Signaling and protection. Antioxid
Redox Signal 18: 288–308, 2013.
61. Hess DT, Matsumoto A, Kim S-O, Marshall HE, and
Stamler JS. Protein S-nitrosylation: Purview and parame-
ters. Nat Rev Mol Cell Biol 6: 150–166, 2005.
62. Hickok JR, Sahni S, Shen H, Arvind A, Antoniou C, Fung
LW, and Thomas DD. Dinitrosyliron complexes are the
most abundant nitric oxide-derived cellular adduct: Biolo-
gical parameters of assembly and disappearance. Free Radic
Biol Med 51: 1558–1566, 2011.
63. Ho GP, Selvakumar B, Mukai J, Hester LD, Wang Y, Gogos
JA, and Snyder SH. S-Nitrosylation and S-palmitoylation
reciprocally regulate synaptic targeting of PSD-95. Neuron
71: 131–141, 2011.
64. Hou Y, Guo Z, Li J, and Wang PG. Seleno compounds
and glutathione peroxidase catalyzed decomposition of
S-nitrosothiols. Biochem Biophys Res Commun 228: 88–93, 1996.
65. Huang Y, Man HY, Sekine-Aizawa Y, Han Y, Juluri K, Luo
H, Cheah J, Lowenstein C, Huganir RL, and Snyder SH.
S-nitrosylation of N-ethylmaleimide sensitive factor medi-
ates surface expression of AMPA receptors. Neuron 46: 533–
540, 2005.
66. Hyman BT, Marzloff K, Wenniger JJ, Dawson TM, Bredt
DS, and Snyder SH. Relative sparing of nitric oxide syn-
thase-containing neurons in the hippocampal formation in
Alzheimer’s disease. Ann Neurol 32: 818–820, 1992.
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1232 MARTÍNEZ-RUIZ ET AL.
89. Lima B, Lam GKW, Xie L, Diesen DL, Villamizar N,
Nienaber J, Messina E, Bowles D, Kontos CD, Hare JM,
Stamler JS, and Rockman HA. Endogenous S-nitrosothiols
protect against myocardial injury. Proc Natl Acad Sci USA
106: 6297–6302, 2009.
90. Lindermayr C, and Durner J. S-Nitrosylation in plants:
Pattern and function. J Proteomics 73: 1–9, 2009.
91. Lipton SA, Choi YB, Pan ZH, Lei SZ, Chen HS, Sucher NJ,
Loscalzo J, Singel DJ, and Stamler JS. A redox-based
mechanism for the neuroprotective and neurodestructive
effects of nitric oxide and related nitroso-compounds.
Nature 364: 626–632, 1993.
92. Lipton SA, Rayudu PV, Choi YB, Sucher NJ, and Chen HS.
Redox modulation of the NMDA receptor by NO-related
species. Prog Brain Res 118: 73–82, 1998.
93. Lipton SA, and Stamler JS. Actions of redox-related con-
geners of nitric oxide at the NMDA receptor. Neuro-
pharmacology 33: 1229–1233, 1994.
94. Liu J, Garcı́a-Cardeña G, and Sessa WC. Palmitoylation of
endothelial nitric oxide synthase is necessary for optimal
stimulated release of nitric oxide: Implications for caveolae
localization. Biochemistry 35: 13277–13281, 1996.
95. Liu L, Hausladen A, Zeng M, Que L, Heitman J, and
Stamler JS. A metabolic enzyme for S-nitrosothiol con-
served from bacteria to humans. Nature 410: 490–494, 2001.
96. Liu L, Yan Y, Zeng M, Zhang J, Hanes MA, Ahearn G,
McMahon TJ, Dickfeld T, Marshall HE, Que LG, and
Stamler JS. Essential roles of S-nitrosothiols in vascular
homeostasis and endotoxic shock. Cell 116: 617–628, 2004.
97. Liu X, Miller MJ, Joshi MS, Thomas DD, and Lancaster JR,
Jr. Accelerated reaction of nitric oxide with O2 within the
hydrophobic interior of biological membranes. Proc Natl
Acad Sci USA 95: 2175–2179, 1998.
98. Lu W, Man H, Ju W, Trimble WS, MacDonald JF, and
Wang YT. Activation of synaptic NMDA receptors induces
membrane insertion of new AMPA receptors and LTP in
cultured hippocampal neurons. Neuron 29: 243–254, 2001.
99. Malik M, Jividen K, Padmakumar VC, Cataisson C, Li L,
Lee J, Howard OM, and Yuspa SH. Inducible NOS-induced
chloride intracellular channel 4 (CLIC4) nuclear transloca-
tion regulates macrophage deactivation. Proc Natl Acad Sci
USA 109: 6130–6135, 2012.
100. Mannick JB, Hausladen A, Liu L, Hess DT, Zeng M, Miao
QX, Kane LS, Gow AJ, and Stamler JS. Fas-induced caspase
denitrosylation. Science 284: 651–654, 1999.
101. Marino SM, and Gladyshev VN. Structural analysis of
cysteine S-nitrosylation: A modified acid-based motif and
the emerging role of trans-nitrosylation. J Mol Biol 395: 844–
859, 2010.
102. Maron BA, Tang SS, and Loscalzo J. S-nitrosothiols and the
S-nitrosoproteome of the cardiovascular system. Antioxid
Redox Signal 18: 270–287, 2013.
103. Martı́nez-Ruiz A, Cadenas S, and Lamas S. Nitric oxide
signaling: Classical, less classical, and nonclassical mecha-
nisms. Free Radic Biol Med 51: 17–29, 2011.
104. Martı́nez-Ruiz A, and Lamas S. S-Nitrosylation: A potential
new paradigm in signal transduction. Cardiovasc Res 62: 43–
52, 2004.
105. Martı́nez-Ruiz A, and Lamas S. Signalling by NO-
induced protein S-nitrosylation and S-glutathionylation:
convergences and divergences. Cardiovasc Res 75: 220–
228, 2007.
106. Martı́nez-Ruiz A, and Lamas S. Two decades of new con-
cepts in nitric oxide signaling: From the discovery of a gas
messenger to the mediation of nonenzymatic posttransla-
tional modifications. IUBMB Life 61: 91–98, 2009.
107. Martı́nez-Ruiz A, Villanueva L, de Orduña CG, López-
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iNOS¼ inducible nitric oxide synthase
LMM¼ low molecular mass
LPS¼ lipopolysaccharide
LTCC¼L-type Ca2+ channel





RNS¼ reactive nitrogen species
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